HeXell-2020 / HeXun Biosciences - LARVOL DELTA

Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Hexun Biosciences Co., LTD. | Trial completion date: Jul 2028 ➔ Jul 2029 | Trial primary completion date: Jan 2028 ➔ Dec 2028

Trial completion date • Trial primary completion date • Geriatric Disorders

Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Hexun Biosciences Co., LTD.

New P1 trial • Geriatric Disorders

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease (clinicaltrials.gov) - P1/2 | N=39 | Not yet recruiting | Sponsor: Hexun Biosciences Co., LTD.

New P1/2 trial • Cardiovascular • Coronary Artery Disease